Department of Medical Oncology, Hospital Clinic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Catalonia, Spain.
Autoimmun Rev. 2011 Feb;10(4):222-7. doi: 10.1016/j.autrev.2010.10.006. Epub 2010 Oct 16.
The pathogenic role of antiphospholipid antibodies (aPL) in the development of venous thromboembolism (VTE) in patients with malignancies has not been established. From May 2006 to April 2008, 258 consecutive patients with solid-organ malignancies who developed VTE (VTE+) were recruited. A group of 142 patients matched for age, sex and tumor type cancer patients without VTE (VTE-) and an age-and-sex matched group of 258 healthy subjects were also included. A second blood sample was taken in positive aPL patients at least 12 weeks later. Twenty-one (8.1%) VTE+ patients, 2 (1.4%) VTE- patients (p=0.006) and 2 (0.8%) healthy subjects (p<0.001) were positive for aPL. Persistent aPL positivity was observed in only 4 out of 15 available VTE+ patients. No differences in demographic characteristics, clinical pattern and outcome were observed in VTE+ patients according to aPL status. The low prevalence and transience of aPL positivity in patients with solid-organ malignancies with VTE argues against a pathogenic role in the development of thrombosis in this setting. The published evidence of the relationship between cancer, aPL, and thrombosis is reviewed.
抗磷脂抗体 (aPL) 在恶性肿瘤患者静脉血栓栓塞症 (VTE) 发展中的致病作用尚未确定。2006 年 5 月至 2008 年 4 月，招募了 258 例发生 VTE（VTE+）的实体恶性肿瘤连续患者。还纳入了年龄、性别和肿瘤类型匹配的 142 例无 VTE（VTE-）的癌症患者组和 258 例年龄和性别匹配的健康对照组。在阳性 aPL 患者中，至少在 12 周后采集第二份血样。21 例（8.1%）VTE+患者、2 例（1.4%）VTE-患者（p=0.006）和 2 例（0.8%）健康对照组为 aPL 阳性。在 15 例可获得的 VTE+患者中，仅 4 例持续存在 aPL 阳性。根据 aPL 状态，VTE+患者的人口统计学特征、临床模式和结局无差异。在患有 VTE 的实体恶性肿瘤患者中，aPL 阳性的低患病率和短暂性表明其在血栓形成中的致病作用不大。本文回顾了癌症、aPL 和血栓形成之间关系的现有证据。
